Confidential

Ethics Committee: Informed Consent

TITLE: EFFECTIVENESS AND SAFETY STUDY TO EVALUATE THE USE OF ORAL IVERMECTIN ASSOCIATED WITH IOTA-CARRAGENIN APPLIED LOCALLY IN THE NASAL AND ORAL CAVITY, IN THE PROPHYLAXIS OF COVID-19 DISEASE IN HEALTHCARE AGENTS

The emergency of COVID-19 requires the urgent development of strategies to avoid the impact of the disease on our population, the saturation of the health system and that allows us to carry out adequate treatments to reduce the mortality of the disease. Upper respiratory tract infection has a major impact on the transmission and pathogenesis of SARSCoV2. The role of saliva and salivary glands in the early stage of viral infection is becoming increasingly well understood. Any measure located in the oral cavity to reduce viral load, will reduce the level of contagion in the social environment of each person. Given that the viral RNA detection diagnostic test is not immediate and that contagion control is essential during the first days of the development of the disease, This treatment, even in suspected cases of COVID-19, contributes to the control of contagion in the first phase of the infection, even when there are no symptoms of the disease. We propose the use of oral Ivermectin, associated with carrageenan applied to nasal and oral mucosa with localized action on saliva and salivary glands. We propose an efficacy and safety study to evaluate the use of oral Ivermectin associated with iota-Carrageenan applied locally in the nasal and oral cavity, in the prophylaxis of COVID-19 disease in health personnel. associated with carrageenan applied to nasal and oral mucosa with localized action on saliva and salivary glands. We propose an efficacy and safety study to evaluate the use of oral Ivermectin associated with iota-Carrageenan applied locally in the nasal and oral cavity, in the prophylaxis of COVID-19 disease in health personnel. associated with carrageenan applied to nasal and oral mucosa with localized action on saliva and salivary glands. We propose an efficacy and safety study to evaluate the use of oral Ivermectin associated with iota-Carrageenan applied locally in the nasal and oral cavity, in the prophylaxis of COVID-19 disease in healthcare agents.

As you are health personnel, you are invited to participate in this study where it will be evaluated by monitoring a medication already approved by the Institute of Regulation: National Administration of Medicines, Food and Medical Technology (ANMAT) of Argentina. However, the ANMAT approved the use in humans of IVERMETNA and IOTA CARRAGENINA but for other therapeutic purposes; Here the use of them is proposed off-label or under treatment of a new indication such as prophylaxis of infection by coronavirus.

objective:To evaluate the effect of oral Ivermectin, associated with iota-carrageenan in repeated doses in the nasal and oral cavity, on the appearance and eventual progression of CoVid-19 disease, for prophylaxis of Covid-19 infection in health workers exposed to the care of suspected or positive patients for Covid-19. As it is a research protocol, your participation will be voluntary and there will be total protection of the confidentiality of your data, and you can refuse or not to participate in it, as well as you can withdraw at the time you want, being your decision not communicated in any way to any person.

Likewise, you will be given the contact information: E-mail address and cell phone number of the research team, so that you can inform the team if there is any undesired effect.

Intervention:It will be carried out in a first visit to each public institution that adheres to the treatment, the monitoring center will be the Hospital Ángel C. Padilla. There I will be given: 1. Carrageenan to put 1 spray in each nostril (2 total puffs in the nostril) and 4 sprays in the oral cavity (under the tongue, one on each side and one in the oropharyngeal area. I am informed

Confidential

that I must carry out this dosage schedule 5 times a day, repeating the scheme every 4 hours. The last dosage schedule of the day should be done prior to night rest, in this case you should not wait for the 4-hour period compared to the previous dose 2. Ivermectin to take in 2 tablets of 6 mg each (total 12 mg) once a week, and this treatment will be repeated for 4 weeks.

If you have symptoms for Coronavirus infection, a nasopharyngeal swab will be performed for diagnosis of COVID-19 by RT-PCR. If your sample tests positive for coronavirus, prophylaxis treatment will be suspended no matter what stage you are in. In this way, you will be able to receive the care proposed by the health team that will be appointed to attend to the positive cases that do not belong to the research team of this study. Once the prophylaxis is suspended, the follow-up phase of the study begins for 30 days.

Total Study Duration:28 days: Intervention Period: with visit 0 at the beginning and 4 visits each week until reaching 28 days; Post Treatment Follow-up Period: 30 days.

Ivermectin Features: Ivermectin is a drug in use for a long time as antiparasitic treatment (vermicide) both in animals and man. Ivermectin is not approved for use in COVID-19.
Although the side effects of ivermentina are mild, very infrequent and all are transitory. These effects are due to the toxic substances released after the vermicidal action. These effects revert after stopping the drug. Likewise, the following hypersensitivity reactions could occur, which are pruritus, conjunctivitis, arthralgias, myalgias (includes abdominal myalgia), fever, edema, nausea, vomiting, diarrhea, adenopathies, orthostatic hypotension, tachycardia, asthenia, rash and headaches. These symptoms are rarely severe. Ophthalmic side effects are rare after treatment, but an abnormal sensation in the eyes, papilledema, anterior uveitis, conjunctivitis, limbites, keratitis, chorioretinitis or choroiditis, that can occur because of a condition of themselves, can be found occasionally during treatment. They are rarely severe and generally disappear without the help of corticosteroids. Symptoms of drowsiness and non-specific transient modifications of the electrocardiogram were reported. Sometimes transient eosinophilia may appear. As ivermectin is contraindicated in pregnancy and lactation. To rule out the probability of pregnancy in women of childbearing age, a pregnancy test will be performed before enrolling the patient in the study. Sometimes transient eosinophilia may appear. As ivermectin is contraindicated in pregnancy and lactation. To rule out the probability of pregnancy in women of childbearing age, a pregnancy test will be performed before enrolling the patient in the study. Sometimes transient eosinophilia may appear. As ivermectin is contraindicated in pregnancy and lactation. To rule out the probability of pregnancy in women of childbearing age, a pregnancy test will be performed before enrolling the patient in the study. There is a possibility that prophylactic treatment with ivermectin may not have a beneficial effect against coronavirus infection. This may provide interesting data along with other investigations to be able to use it after the analysis of the data collected.

Characteristics of Iota-Carrageenan: IOTA CARRAGENINA is a sulphated polysaccharide obtained from red algae (rodophyceae). It is a natural antiviral with proven activity against rhinovirus, influenza A-H1N1, herpes, hepatitis A and papilloma virus. PROTECTION: Creates a protective layer on the surface of the nasal mucosa preventing the adhesion of the virus to the cells and inhibiting its replication. Iota carrageenan demonstrated clinical efficacy against rhinovirus, influenza A-H1N1, and common cold coronavirus. It is indicated in adults and children from 1 year. There are not enough data records on its use in pregnancy, therefore its use in this population is not recommended. IN VITRO EFFECTIVENESS in vitro efficacy was demonstrated against SARS-COV-2.

Confidential

Several Research studies are in progress, but they need more time to get results. The Ministry of Health of Tucumán has evaluated the different drugs that are being tested in studies that are in progress and others that have been completed and, after the opinion of research experts, considers that the use of ivermectin with iota-carrageenan as prophylaxis for Preventing coronavirus infection in health personnel exposed to suspected or positive coronavirus patients would be an alternative.

Your participation in the study is voluntary, and if you agree to participate, you can still withdraw from the study at any time. This will not affect your care or your working conditions. All your data will be confidential and only the researchers will know your identity.

There will be no cost to participate and you will not be paid to participate.

Data from the study researcher to be able to communicate with Lic. Marcelo Fabio Morales, who can be contacted at any time during the study. Email: moralesmarcelofabio@gmail.com Tel.- 0381 5 193332

Informed consent

I have been informed that I can participate in this research study to test the effect of ivermectin and iota carrageenan as a preventive treatment to avoid coronavirus infection.

I understand that the drug ivermectin and iota-carrageenan is currently approved by the National Administration of Medicines, Food and Medical Technology (ANMAT) but only for use as a vermicide and that it is not yet approved for use in prevention or infection by Coronavirus.

The Ministry of Public Health of Tucumán and the researchers responsible for this study may suspend the carrying out of this study for different reasons at any stage of its development.

I give my consent to receive the prophylactic treatment with ivermectin and iota-carrageenan, proposed by the researchers of the Ministry of Health of the Province of Tucumán for my infection by Coronavirus COVID-19.

Patient Name_____

DNI_____

Date_____

Name of Witness (if applicable) _____

DNI_____

Date_____

Investigator's Name_____

DNI_____

Date_____

Confidential

The Health Research Directorate will be in charge of Project Management. Central Committee of Tucumán- Argentina -. Email : cei-tucuman@msptuuman.gov.ar. Registered in the National Registry of Ethics Committees in Argentina in the RENIS Base: Number: 0032 (RENIS: National Registry of Health Research) and Health Research Directorate - SIPROSA - Tucumán- Argentina E-mail: dir_investigacion@msptucuman.gov.ar